Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy

Multiple Sclerosis Journal

Volumn 17, Issue 4, 2011, Pages 423-430

  Sandberg Wollheim, Magnhild ^a   Alteri, Enrica ^b   Moraga, Margaretha Stam ^b   Kornmann, Gabrielle ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b MERCK SERONO S A   (Switzerland)

Author keywords

multiple sclerosis; pregnancy; safety; subcutaneous interferon beta 1a

Indexed keywords

BETA1A INTERFERON;

ADULT; ANENCEPHALUS; ARTICLE; BONE MALFORMATION; CLEFT LIP; CLUBFOOT; CONGENITAL MALFORMATION; CONTROLLED STUDY; CORNEA DISEASE; CORPUS CALLOSUM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOWN SYNDROME; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; DWARFISM; ECTOPIC PREGNANCY; FALLOT TETRALOGY; FEMALE; FETUS HYDROPS; FETUS MALFORMATION; FINGER MALFORMATION; FOOT MALFORMATION; HAND MALFORMATION; HEART ARREST; HEART DISEASE; HUMAN; HYDATIDIFORM MOLE; HYDROCEPHALUS; INTRAUTERINE GROWTH RETARDATION; LIMB MALFORMATION; LIVE BIRTH; LUNG HYPOPLASIA; MAJOR CLINICAL STUDY; MEDICAL ABORTION; MENINGOMYELOCELE; MICROGYRIA; MICROTIA; MULTIPLE SCLEROSIS; MUSCULOSKELETAL DISEASE; NEURAL TUBE DEFECT; ORBIT DISEASE; PREGNANCY OUTCOME; PRENATAL EXPOSURE; RESPIRATORY ARREST; RIB HYPOPLASIA; SEX CHROMOSOME ABERRATION; SIDE EFFECT; SKULL DEFECT; SOLITARY KIDNEY; SPINA BIFIDA; SPINE MALFORMATION; SPONTANEOUS ABORTION; STILLBIRTH; STURGE WEBER SYNDROME; SYNDROME VACTERL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; TURNER SYNDROME;

EID: 79954602080     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510394610     Document Type: Article

References (26)

1. Weinshenker BG, Bass B., Rice GP, Noseworthy J., Carriere W., Baskerville J., et al. The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain 1989 ; 112: 133 146. (Pubitemid 19056478)
2. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996 ; 39: 285 294. (Pubitemid 26100751)
3. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 1998 ; 352: 1498 1504.
4. PRISMS Study Group, University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001 ; 56: 1628 1636.
5. Mueller B., Zhang J. and Critchlow C. Birth outcomes and need for hospitalization after delivery among women with multiple sclerosis. Am J Obstet Gynecol 2002 ; 186: 446 452. (Pubitemid 34234155)
6. Boskovic R., Wide R., Wolpin J., Bauer DJ and Koren G. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology 2005 ; 65: 807 811. (Pubitemid 41362119)
7. De Las Heras V., de Andres C., Tellez N. and Tintore M. Pregnancy in multiple sclerosis patients treated with immunomodulators prior to or during part of the pregnancy: a descriptive study in the Spanish population. Mult Scler 2007 ; 13: 981 984. (Pubitemid 351541432)
8. Fernandez Liguori N., Klajn D., Acion L., Caceres F., Calle A., Carra A., et al. Epidemiological characteristics of pregnancy, delivery, and birth outcome in women with multiple sclerosis in Argentina (EMEMAR study). Mult Scler 2009 ; 15: 555 562.
9. Fragoso YD, Finkelsztejn A., Comini-Frota ER, da Gama PD, Grzesiuk AK, Khouri JM, et al. Pregnancy and multiple sclerosis: the initial results from a Brazilian database. Arq Neuropsiquiatr 2009 ; 67: 657 660.
10. Hellwig K., Brune N., Haghikia A., Muller T., Schimrigk S., Schwodiauer V., et al. Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. Acta Neurol Scand 2008 ; 118: 24 28. (Pubitemid 351809326)
11. Patti F., Cavallaro T., Lo Fermo S., Nicoletti A., Cimino V., Vecchio R., et al. Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis? J Neurol 2008 ; 255: 1250 1253.
12. Sandberg-Wollheim M., Frank D., Goodwin TM, Giesser B., Lopez-Bresnahan M., Stam-Moraga M., et al. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology 2005 ; 65: 802 806. (Pubitemid 41362118)
13. Weber-Schoendorfer C. and Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler 2009 ; 15: 1037 1042.
14. Buttmann M. and Rieckmann P. Interferon-beta1b in multiple sclerosis. Expert Rev Neurother 2007 ; 7: 227 239.
15. Ferrero S., Pretta S. and Ragni N. Multiple sclerosis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol 2004 ; 115: 3 9. (Pubitemid 38844209)
16. Teva Pharmaceuticals. Copaxone prescribing information. http://www.copaxone.com/pdf/PrescribingInformation.pdf, consulted 19 October 2010.
17. Biogen Idec. Tysabri Summary of Product Characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000603/WC500044686.pdf, consulted 19 Oct 2010.
18. European Medicines Agency. Guideline on the Exposure to Medicinal Products During Pregnancy: Need for Post-authorisation Data (EMEA/CHMP/313666/ 2005). http://www.emea.eu.int/pdfs/human/phvwp/31366605en.pdf, consulted 16 Nov 2009.
19. Koren G. Medication Safety in Pregnancy and Breastfeeding. New York, USA: McGraw-Hill, Health Professions Division, 2007.
20. Regan L. and Rai R. Epidemiology and the medical causes of miscarriage. Baillieres Best Pract Res Clin Obstet Gynaecol 2000 ; 14: 839 854.
21. Foulds P., Wellsley MA, Richman SR and Onigman T. Pregnancy outcomes from the Avonex (Interferon beta-1a) Pregnancy Exposure Registry. Neurology 2010 ; 74 (Suppl 2). A364.
22. Coyle PK, Johnson KP, Pardo L., Stark Y. Pregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate (Copaxone). Neurology 2003 ; 60 (Suppl 1). A60.
23. Cristiano L., Bozic C. and Koojimans-Coutinho M. Preliminary evaluation of pregnancy outcomes from the TYSABRI (Natalizumab) Pregnancy Exposure Registry. Neurology 2010 ; 74 (Suppl 2). A66.
24. Bayer Inc. Betaseron (interferon beta-1b) Prescribing Information. http://www.betaseron.com/prescribing-info.jsp, consulted 19 October 2010.
25. Pons JC, Lebon P., Frydman R. and Delfraissy JF Pharmacokinetics of interferon-alpha in pregnant women and fetoplacental passage. Fetal Diagn Ther 1995 ; 10: 7 10.
26. Tremlett HL and Oger J. Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective. Mult Scler 2008 ; 14: 94 105. (Pubitemid 351541402)